



Company: Fuji Pharma Co., Ltd  
(Code No: 4554 Tokyo Stock Exchange, First Section)  
Representative Director: Hirofumi Imai,  
President and Chief Executive Officer  
TEL: +81-03-3556-3344

15<sup>th</sup> October 2013

## **Announcement of Transfer of Distribution and Sales Right of Optiray™ Contrast Agent**

Fuji Pharma Co., Ltd (Head Office: Chiyoda-ku, Tokyo, President and Chief Executive Officer: Hirofumi Imai, hereinafter called “Fuji”) is pleased to announce its agreement with Mallinckrodt Plc through its subsidiaries Mallinckrodt Japan Co. Ltd. and Mallinckrodt AG (both of which are subsidiaries of Mallinckrodt Plc) whereby the distribution and sales rights of Optiray™ (ioversol injection) contrast agent is to be transferred to Fuji.

### **1. The objective of the transfer**

The theme of Fuji’s current medium-term business plan is “Good to Great.” By 2015 – when it is the company’s 50 year anniversary – Fuji intends to expand its existing core business area and design a new business execution structure, which will be handed down to the next generation as a new operating framework.

This agreement was realized based on the following objectives of the two companies. Fuji intends to expand the area of acute medical business, and Mallinckrodt Japan intends to focus on new business development and expansion of the Mallinckrodt global product portfolio in Japan as part of a new, independent company.

This distribution agreement enables Fuji to offer a wider range of products in addition to its existing products such as Oypalomin (iopamidol injection) and Iopaque (iohexol injection) and to support even more patients in the acute medical field.

### **2. Product outline**

Optiray was developed by Mallinckrodt and started to be sold in the US in 1989. In Japan, Mallinckrodt Japan’s predecessor (Mallinckrodt Medical Co. Ltd.) obtained the

marketing authorization and started to sell Optiray in 1992. It has now been approved and sold in more than 50 countries worldwide and has been used by thousands of medical institutions since its introduction to the market.

### 3. Schedule

1) A board of directors' meeting	15 <sup>th</sup> October, 2013
2) Date of starting sales	1 <sup>st</sup> December, 2013 (to be confirmed)

### 4. Corporate Profile

#### ■ Mallinckrodt plc

Independent publicly traded company as of: June 28, 2013

Head Office: Dublin, Ireland

Representative Director: Mark Trudeau, President and Chief Executive Officer

Revenue: USD 2.1 billion

Business Activities: Mallinckrodt Pharmaceuticals is a leading global specialty pharmaceuticals business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Pharmaceuticals has approximately 5,500 employees worldwide with sales in roughly 70 countries. To learn more about Mallinckrodt, please visit [www.mallinckrodt.com](http://www.mallinckrodt.com).

#### ■ Mallinckrodt AG

Established: February 2013

Head Office: Hinterbergstrasse 20, 6330 Cham, Switzerland

Representative Director: Dale Rees

Capital: CHF 100,000

Business Activities: Production, import, export, distribution and sales of pharmaceutical products, pharmaceutical ingredients, diagnostic drugs and medical devices. Development, acquisition, holding and disposition of related intellectual property rights.

#### ■ Mallinckrodt Japan

Established: August 2012

Head Office: 1-4-14 Koraku Bunkyo-ku Tokyo

Representative Director: Takashi Ueda

Capital: ¥ 50 million

Business Activities: Production, import, sales of pharmaceutical products, pharmaceutical ingredients, and diagnostic drugs.

#### 5. Next Step

The impact of this distribution agreement on Fuji's consolidated performance for this year (fiscal year ending September 2014) is currently being calculated and will be disclosed once it is finalized.